Actively Recruiting
Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial
Led by Khawaja Danish Ali · Updated on 2026-03-02
130
Participants Needed
1
Research Sites
12 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will compare the outcomes of Vericuguat and placebo in patient with decompensated heart failure . This study will carry out after approval from IERB. Seventy patients fulfilling the inclusion criteria will be enrolled from emergency department. Informed consent will be taken from attendants. A detailed history including name, age, gender, duration of heart failure, history of alcoholism, smoking, diabetes, hypertension, EF at baseline and NYHA class will be noted. Patients will be randomly divided in two groups by using lottery method. Outcomes will be assessed at in terms of hospitalization for heart failure, death from cardiovascular event and side effects.
CONDITIONS
Official Title
Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with decompensated heart failure with left ventricular ejection fraction 45% or less
- Patients presenting with NYHA functional class III-IV symptoms or worsening class II symptoms
- Elevated natriuretic peptide levels (NT-proBNP >1000 pg/mL for sinus rhythm or >1600 pg/mL for atrial fibrillation) without other causes of elevation
You will not qualify if you...
- Blood pressure less than 100 mmHg
- Current or planned use of long-acting nitrates, soluble guanylate cyclase stimulators, or phosphodiesterase type 5 inhibitors
- Use of intravenous inotropes or having an implantable left ventricular assist device
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Armed Forces Institute of Cardiology. Pakistan
Rawalpindi, Punjab Province, Pakistan, 46000
Actively Recruiting
Research Team
D
Dr Khawaja Danish Ali, MBBS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here